Combination checkpoint blockade - Taking melanoma immunotherapy to the next level

New England Journal of Medicine

Volumn 369, Issue 2, 2013, Pages 187-189

  Riley, James L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PD 1; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LUNG NON SMALL CELL CANCER; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MELANOMA; MONOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION;

EID: 84880279552     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1305484     Document Type: Editorial

References (10)

1. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
2. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
3. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704. (Pubitemid 351600389)
4. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
5. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005;25:9543-53. (Pubitemid 41507854)
6. Wherry EJ. T cell exhaustion. Nat Immunol 2011;12:492-9.
7. Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013 April 7 (Epub ahead of print).
8. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
9. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
10. Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013 May 10 (Epub ahead of print).